Key Highlights
- Bavarian Nordic A/S reported a 30% increase in its Travel Health business for 2025.
- The company’s rabies and Tick-Borne Encephalitis vaccines saw significant growth, with increases of 34% and 20%, respectively.
- First-year sales of the chikungunya vaccine (VIMKUNYA®) reached DKK 85 million ($13.4 million).
Bavarian Nordic’s Travel Vaccine Surge: A Business Perspective
Bavarian Nordic A/S is breathing new life into its travel vaccines, with a 30% increase in its Travel Health business for the year 2025. This surge comes as international travel forecasts predict an uptick in global wanderlust.
Existing Vaccine Success
The company’s existing rabies and Tick-Borne Encephalitis vaccines are showing impressive growth, with increases of 34% and 20%, respectively. These numbers indicate a strong customer demand that Bavarian Nordic is capitalizing on.
“We are encouraged by these extraordinary results,” stated Paul Chaplin, President and CEO of Bavarian Nordic. “Our commitment to providing robust travel health solutions is paying off.”
New Vaccine Launch
Adding to the mix, the first-year sales of the chikungunya vaccine (VIMKUNYA®) reached DKK 85 million ($13.4 million). This marks a significant milestone for Bavarian Nordic as it expands its portfolio into mosquito-transmitted diseases.
The chikungunya virus has affected over 100 countries since its emergence, with Florida reporting numerous travel-related cases in early 2026. The state’s local case adds to the urgency of such vaccines.
Global Health Context
While global international travel activity only increased by 4% from 2024 to 2025, according to data from UN Tourism, Bavarian Nordic’s vaccine business is outperforming expectations. This suggests a growing awareness among travelers of the need for preventative health measures.
Bavarian Nordic remains the leading provider to governments for mpox and smallpox vaccines, supporting public health responses during outbreaks or long-term stockpiling needs. The company continues to build strong partnerships to expand its business base.
Conclusion
The success of Bavarian Nordic’s travel vaccines is a testament to the growing importance of preventive healthcare in international travel. With the first-year sales of VIMKUNYA® reaching DKK 85 million, it’s clear that these products are meeting a significant market need.
